SEC Tracker
Get the app

Zentalis Pharmaceuticals ZNTL

Zentalis Pharmaceuticals reports Q3 2026 financial results

Zentalis Pharmaceuticals (ZNTL) filed an 8-K with the SEC on Nov 9, 2026, 4:09 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities of $228.9 million as of September 30, 2026
  2. DENALI Part 2c enrollment scheduled to complete in November 2026
  3. Azenosertib's DENALI Part 1b survival data showed median OS of 15.9 months for Cyclin E1-positive PROC patients

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Zentalis Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.